← All trials
NCT06227832
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2023
- Primary completion
- Mar 15, 2024
- Completion date
- Jul 31, 2024
- First posted
- Jan 29, 2024
- Last posted
- Mar 27, 2024
- Enrollment
- 38
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kaken Pharmaceutical Co.,Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.